You’d think that facing down some of the toughest, most challenging diseases to date would scare some people. The unpredictability, the unknowable, is not to be taken lightly when developing life-saving treatments. But at AbbVie, researchers know there’s a specific kind of joy they take in the uncertainty of their work. They thrill at the possibility that every day presents a totally different, and often unprecedented, challenge. It turns out, there’s no real way to predict anything in the lab. AbbVie’s R&D teams understand this truth on a deep level, knowing that their mission is to chart completely unexplored scientific territory and to chase down the unknown.
Chasing the Unknown


A tailored approach to medicine could fundamentally change how we look at treating patients.


From Chicago to sub-Saharan Africa, a team of scientists paired up with a nonprofit research organization to help find a treatment for a disease affecting millions.
Scientists who take risks and learn from their failures open up a whole new frontier of possibilities

A tailored approach to medicine could fundamentally change how we look at treating patients.

From Chicago to sub-Saharan Africa, a team of scientists paired up with a nonprofit research organization to help find a treatment for a disease affecting millions.
Scientists who take risks and learn from their failures open up a whole new frontier of possibilities
Vox Media’s Epic Stories and The Explainer Studio dug into the fearlessness and determination of AbbVie researchers to find medical treatments for all types of diseases. Watch and read on to get a behind-the-scenes look at AbbVie’s R&D team: how they overcome obstacles in pursuit of a cure for river blindness, how they operate in the shadow of failure, and more.
Everything in Chasing the Unknown


Three ways this team kept advancing potentially life-saving medications during a pandemic.


Inside the mission to invent the equipment and technologies needed for tomorrow’s scientific discoveries.


How Eric Karran stays motivated when tackling two of the greatest neurological mysteries.

